I-Mab Successfully Raised USD 220 Million in Series C Funding

SHANGHAI, June 29, 2018 -- (Healthcare Sales & Marketing Network) -- I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD 220 mi... Biopharmaceuticals, Oncology, Venture Capital I-Mab Biopharma, Genexine, HyLeukin, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news